Fig. 6. Effect of CHD3^NEMO on tumor growth in a traceable reporter BC-3-Luc PEL xenograft mouse model.

a Box- and Whisker plots of relative tumor burden at day 20 post-engraftment quantified using bioluminescence imaging. Statistical analysis was performed using two-sided Mann Whitney test (p = 0.012, *p ≤ 0.05). One representative mice for each group is presented (right). Box and whisker plots represent all individual data points within the /min-max range (vehicle n = 10 and treated n = 5). b Bioluminescence quantitation representing tumor burden (mean ± SEM) after 20 days of tumor engraftment in the vehicle-treated (blue line, n = 10) versus CHD3^NEMO treated group (red line, n = 5). Statistical analysis was performed using two-sided Mann Whitney test (p = 0.012, *p ≤ 0.05). c Kaplan-Meier survival analysis showing that mice treated with the CHD3^NEMO peptide (in red) has a survival advantage compared to the control group (in blue). The difference in survival curves was analyzed by log-rank (Mantel-Cox) test (P = 0.002). d Mice treated with CHD3^NEMO for 24 h have attenuated NF-κB signaling in tumor cells.